Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Passes Above 200-Day Moving Average of $10.72

Global X Genomics & Biotechnology ETF (NASDAQ:GNOMGet Free Report)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.72 and traded as high as $11.25. Global X Genomics & Biotechnology ETF shares last traded at $11.21, with a volume of 52,213 shares traded.

Global X Genomics & Biotechnology ETF Stock Up 1.0 %

The business has a 50 day moving average of $11.18 and a 200 day moving average of $10.72. The company has a market capitalization of $92.26 million, a P/E ratio of -4.79 and a beta of 1.03.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of large investors have recently made changes to their positions in GNOM. Money Concepts Capital Corp purchased a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth $25,000. IFP Advisors Inc lifted its position in shares of Global X Genomics & Biotechnology ETF by 121.0% during the second quarter. IFP Advisors Inc now owns 3,521 shares of the company’s stock valued at $53,000 after buying an additional 1,928 shares during the last quarter. Advisor Group Holdings Inc. lifted its position in Global X Genomics & Biotechnology ETF by 26.9% during the fourth quarter. Advisor Group Holdings Inc. now owns 3,916 shares of the company’s stock valued at $49,000 after acquiring an additional 831 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $100,000. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Global X Genomics & Biotechnology ETF by 19.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,200 shares of the company’s stock worth $116,000 after acquiring an additional 1,493 shares during the last quarter. 56.95% of the stock is currently owned by institutional investors.

About Global X Genomics & Biotechnology ETF

(Get Free Report)

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.

Read More

Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.